In 2024, a net loss is anticipated to exceed 0.6 billion; Hangzhou Century resorts to selling land to "ease its troubles" after financial fraud | Interpretations

① Hangzhou Century expects a net income loss attributable to shareholders of the listed company of 0.419 billion yuan to 0.629 billion yuan for the fiscal year 2024, with narrowing losses; ② Hangzhou Century was heavily fined by regulators for fabricating false content in the 2019 and 2020 annual reports as well as in the 2021 Convertible Bonds public issuance documents; ③ To alleviate cash flow issues, the company plans to sell assets.

cls.cnJan 15 20:22

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

The State-owned Assets Supervision and Administration Commission, together with the National Development and Reform Commission, jointly introduced a significant venture capital policy, and the equity market is expected to usher in a period of development

1. The State-owned Assets Supervision and Administration Commission of the State Council and the National Development and Reform Commission jointly introduced policy measures to promote the high-quality development of central enterprises' venture capital funds, support central enterprises in initiating the establishment of venture capital funds, focusing on early-stage, small-scale, long-term, and hard technology investments. 2. Citic Sec research reports pointed out that, against the backdrop of entering a valuation expansion cycle in the secondary market, as the linkage effects between the primary and secondary markets become increasingly close, the equity market will also move towards a period of high-quality development and prosperity.

cls.cnDec 3, 2024 08:02

Is Guangxi Wuzhou Zhongheng Group planning to sell the controlling stake of Chongqing Lummy Pharmaceutical after years of consecutive losses? | Quick read announcement

①Guangxi Wuzhou Zhongheng Group intends to transfer the shares held directly in Chongqing Lummy Pharmaceutical through public solicitation, and the controlling shareholder and actual controller of the latter may change. ②The story of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019 and became a major shareholder of Chongqing Lummy Pharmaceutical in April of the following year, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical since then. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous loss-making state.

cls.cnNov 26, 2024 22:55

Abnormal trading investigation! The big bull stock special treat Jingfeng has been suspended for the first time, with an increase of over 752% in more than four months | Quick read of the announcement.

①*ST Jingfeng suspended trading for the first time this year due to abnormal fluctuations; ② The cumulative deviation of the closing price for two consecutive trading days reached 15.39%; ③ The stock price has increased by 752.78% in the past four months; ④ There is still uncertainty about the highly anticipated pre-restructuring matters.

cls.cnNov 17, 2024 19:31

Zhangzhou Pientzehuang Pharmaceutical has acquired shares in Fujian Cosunter Pharmaceutical? The innovative drugs track sees the resurgence of players in the traditional chinese medicine industry | Speed-read announcement

fujian cosunter pharmaceutical announced that Yuanshan Fund plans to become a shareholder with a transfer payment of nearly 0.2 billion yuan, holding more than 5% of the company's shares. Yuanshan Fund partners include state-owned wholly-owned companies, zhangzhou pientzehuang pharmaceutical wholly-owned subsidiaries, among which Zhangzhou Pientzehuang Investment is the largest limited partner in terms of fund contribution proportion.

cls.cnNov 16, 2024 00:14